脾氨肽口服液辅助治疗对重症肺炎患儿细胞免疫及炎性因子的影响

Effects of Adjuvant Treatment of Spleen Amino Peptide Oral Liquid on Cellular Immunity and Inflammatory Factors in Children with Severe Pneumonia

目的:探讨脾氨肽口服液辅助治疗对重症肺炎患儿细胞免疫及炎性因子的影响。方法:选取徐州儿童医院2016年2月至2018年3月收治的重症肺炎患儿85例,按完全随机化方法分为常规组(n=42)和联合组(n=43),常规组采用常规西药治疗,联合组采用脾氨肽口服液配合常规西药治疗,比较治疗前后细胞免疫及炎性因子变化、临床疗效和药物不良反应。结果:治疗后两组患儿CD4+、CD4+/CD8+均升高(P<0. 05),CD8+、血清IL-10、IL-17和TGF-β1水平均降低(P<0. 05);联合组CD4+、CD4+/CD8+均高于常规组(P<0. 05),CD8+、血清IL-10、IL-17和TGF-β1水平均低于常规组(P<0. 05)。联合组总有效率为97. 67%,高于常规组的85. 71%,两组比较差异有统计学意义(P<0. 05);两组药物不良反应发生率比较差异无统计学意义(P>0. 05)。结论:对重症肺炎患儿给予脾氨肽口服液辅助治疗,能够改善细胞免疫指标,控制炎性因子水平,增强临床疗效,且未增加药物不良反应。

Objective: To probe into the effects of adjuvant treatment of spleen amino peptide oral liquid on cellular immunity and inflammatory factors in children with severe pneumonia. Methods: A total of 85 children with severe pneumonia admitted to Xuzhou Children’s Hospital from Feb. 2016 to Mar. 2018 were randomly divided into the routine group( n = 42) and the combined group( n =43). The routine group was treated with routine western medicine,while the combined group received spleen amino peptide oral liquid combined with routine western medicine. Changes of cellular immunity and inflammatory factors before and after treatment,clinical efficacy and adverse drug reactions of two groups were compared. Results: After treatment,the levels of CD4+,CD4+/CD8+increased in both groups( P<0. 05),while the levels of CD8+,IL-10,IL-17 and TGF-β1 decreased( P<0. 05). The levels of CD4+and CD4+/CD8+in the combined group were higher than those in the routine group( P<0. 05),and the levels of CD8+,IL-10,IL-17 and TGF-β1 were lower than those in the routine group( P<0. 05). The total effective rate of the combined group was 97. 67%,higher than 85. 71%of the routine group,and the difference was statistically significant( P< 0. 05). There was no significant difference in the incidence of adverse drug reactions between two groups( P > 0. 05). Conclusion: Adjuvant treatment of spleen amino peptide oral liquid in the treatment of children with severe pneumonia can improve the cellular immunity,control the levels of inflammatory factors,enhance the clinical efficacy,with lower incidence of adverse drug reactions.